Market Analysis - NHAI 2017
Nosocomial infections (NI) or hospital acquired infections (HAI) are one of the major complications for health care professionals to tackle. Every day, NI results in prolonged hospital stays, long-term disability, and increased resistance of microorganisms to antimicrobials, massive additional costs for health systems, high costs for patients and their family, and unnecessary deaths. NI represents the most frequent adverse event during care delivery and no institution or country can claim to have solved the problem yet. Based on data from a number of countries, it can be estimated that each year, hundreds of millions of patients around the world are affected by NI.
An in-depth analysis and forecast of selected areas of the global Nosocomial infections and Healthcare Acquired Infections (NHAI) market was done. It includes hospitals, nursing homes, diagnostics, outpatient surgery centres and dialysis centres.
The focus of this report is on selected devices, pharmaceuticals and environmental products currently used or under development for treatment of viral, bacterial and fungal infections.
The global market for selected NHAI treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.
The global hospital acquired infections testing market is poised to grow at a compound annual growth rate (CAGR) of around 19.1% over the next decade to reach approximately $2.75 billion by 2025.
Estimated cost of treating resistant infections in U.S. health care system is about $21 billion to $34 billion annually
Conference Series invites all the participants from all over the world to attend “World Summit on Nosocomial and Healthcare associated Infections” (NHAI 2017) scheduled during October 02-04, 2017 in Las Vegas, USA. Nosocomial Infections 2017 brings together the global leaders in Nosocomial Infections and Healthcare to present their research at this exclusive scientific program. The Nosocomial Infections conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of infectious diseases, immunology, microbiology, infection prevention and infection control. Nosocomial Infections 2017 Organizing Committee also invites young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions.
Nosocomial Infections (NIs) or Hospital-Acquired Infections (HAIs) are a major complication for professionals of health care to tackle. Every day, NIs results in longer hospital stays, long-term disability, and increasing the resistance of microorganisms to antimicrobials, additional massive costs to health care systems, high costs for patients and their families, and unnecessary deaths. Prevention and infection control is needed to prevent transmission of infectious diseases in all health care settings. Infection prevention and control demands a basic understanding of the epidemiology of diseases, risk factors that increase patient susceptibility to infection, and the practices, procedures and treatments that may result in infections. The risk of acquiring Nosocomial infections is related to the mode of transmission of the infectious agent (e.g. Clostridium difficile -CDI, Surgical Site Infections-SSI, Carbapenem-resistant Enterobacteriacae -CRE, Methicillin-resistant Staphylococcus aureus-MRSA, etc.) and the type of patient-care activity or procedure being performed and the underlying patient’s host defences.
The conference attains significance when we look at the Data and Statistics of Nosocomial Infections (NIs) or Hospital Acquired Infections (HAIs) by Centre for Disease Control and Prevention (CDC) .In 2014, the results of a project known as HAI Prevalence Survey were published. The survey describes the burden of nosocomial infections in US hospitals, and reported that in 2011 there were about 722,000 NIs in US acute care hospitals. In addition, approximately 75,000 patients with NIs died during their hospitalization. More than half of all hospital infections took place outside the intensive care unit.
Who should attend?
- Infectious Disease Consultants
- Medical Laboratory Specialists
- Internal Medicine Consultants
- Infection Control Personnel
- Health Care Professionals
- Laboratory Technologists
- Infection Control Nurses
- Patient Safety Managers
- Medical Technologists
- Clinical Scientists
Why to attend?
With members from around the world focused on learning about global trends on emerging infectious diseases and its advances in therapeutic and diagnostic market, this is your best opportunity to reach the largest assemblage of participants from the Infectious diseases community. This particular conference conduct presentations, distributes information, conducts meetings with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2 day event. World renowned speakers, the most recent therapeutic and diagnostic techniques, developments, and the Novel technologies and therapeutic measures for Nosocomial infection and Healthcare are hallmarks of this conference.